Pfizer slipped 0.5% premarket as investors reacted to the company cutting its BioNTech stake by 54.7%, leaving 1.66 million ADS. This overshadowed the completion of its Metsera acquisition, which adds several obesity and cardiometabolic drug candidates, including a GLP-1 nearing Phase 3. Retail sentiment on Stocktwits stayed upbeat, expecting further momentum.